You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-L-Iduronidase for Hurler Disease

Janson, Christopher G. MD*,‡,§; Romanova, Liudmila G. PhD; Leone, Paola PhD§; Nan, Zhenhong PhD*; Belur, Lalitha PhD; McIvor, R. Scott PhD; Low, Walter C. PhD*

doi: 10.1227/NEU.0000000000000157
Research-Animal:Editor' Choice
Editor's Choice

BACKGROUND: Hurler disease (mucopolysaccharidosis type I [MPS-I]) is an inherited metabolic disorder characterized by deficiency of the lysosomal enzyme α-L-iduronidase (IDUA). Currently, the only therapies for MPS-I, enzyme replacement and hematopoietic stem cell transplantation, are generally ineffective for central nervous system manifestations.

OBJECTIVE: To test whether brain-targeted gene therapy with recombinant adeno-associated virus (rAAV5)-IDUA vectors in an MPS-I transgenic mouse model would reverse the pathological hallmarks.

METHODS: Gene therapy approaches were compared using intraventricular or endovascular delivery with a marker (rAAV5-green fluorescent protein) or therapeutic (rAAV5-IDUA) vector. To improve the efficiency of brain delivery, we tested different applications of hyperosmolar mannitol to disrupt the blood-brain barrier or ependymal-brain interface.

RESULTS: Intraventricular delivery of 1 × 1011 viral particles of rAAV5-IDUA with systemic 5 g/kg mannitol co-administration resulted in IDUA expression throughout the brain, with global enzyme activity >200% of the baseline level in age-matched, wild-type mice. Endovascular delivery of 1 × 1012 viral particles of rAAV5-IDUA to the carotid artery with 29.1% mannitol blood-brain barrier disruption resulted in mainly ipsilateral brain IDUA expression and ipsilateral brain enzyme activity 42% of that in wild-type mice. Quantitative assays for glycosaminoglycans showed a significant decrease in both hemispheres after intraventricular delivery and in the ipsilateral hemisphere after endovascular delivery compared with untreated MPS-I mice. Immunohistochemistry for ganglioside GM3, another disease marker, showed reversal of neuronal inclusions in areas with IDUA co-expression in both delivery methods.

CONCLUSION: Physiologically relevant biochemical correction is possible with neurosurgical or endovascular gene therapy approaches for MPS-I. Intraventricular or endovascular delivery of rAAV5-IDUA was effective in reversing brain pathology, but in the latter method, effects were limited to the ipsilateral hemisphere.

ABBREVIATIONS: ECA, external carotid artery

GAG, glycosaminoglycans

GFP, green fluorescent protein

g.p., genomic particles

IA, intra-arterial

ICA, internal carotid artery

ICV, intracerebral ventricular

IDUA, α-L-iduronidase

MPS-I, mucopolysaccharidosis type I

rAAV, recombinant adeno-associated virus

scAAV, self-complimentary adeno-associated virus

Author Information

*Department of Neurosurgery,

Department of Neurology,

Department of Medicine, and

Genetics and Cell Biology, University of Minnesota, School of Medicine

§Cell & Gene Therapy Center, University of Medicine and Dentistry of New Jersey School of Medicine

Correspondence: Christopher G. Janson, MD, 500 Harvard St, Minneapolis, MN 55455. E-mail:

Received February 03, 2013

Accepted September 03, 2013

Copyright © by the Congress of Neurological Surgeons